Cryo-Cell International (Cryo-Cell International) Cash-to-Debt

: 0.09 (As of Feb. 2024)

View and export this data going back to . Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cryo-Cell International's cash to debt ratio for the quarter that ended in Feb. 2024 was 0.09.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Cryo-Cell International couldn't pay off its debt using the cash in hand for the quarter that ended in Feb. 2024.

The historical rank and industry rank for Cryo-Cell International's Cash-to-Debt or its related term are showing as below:

CCEL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09 Med: 1.09 Max: No Debt
Current: 0.09

During the past 13 years, Cryo-Cell International's highest Cash to Debt Ratio was No Debt. The lowest was 0.09. And the median was 1.09.

CCEL's Cash-to-Debt is ranked worse than
83.64% of 654 companies
in the Healthcare Providers & Services industry
Industry Median: 0.74 vs CCEL: 0.09

Cryo-Cell International Cash-to-Debt Historical Data

The historical data trend for Cryo-Cell International's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cryo-Cell International Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Cash-to-Debt

0.83

1.67

2.96

0.15

0.09

Cryo-Cell International Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Cash-to-Debt																0.20	0.15	0.10	0.09	0.09

Competitive Comparison

For the Medical Care Facilities subindustry, Cryo-Cell International's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cryo-Cell International Cash-to-Debt Distribution

For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Cryo-Cell International's Cash-to-Debt falls into.

Cryo-Cell International Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Cryo-Cell International's Cash to Debt Ratio for the fiscal year that ended in Nov. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.98	/	(1.614	+	9.282)
	=	0.09

Cryo-Cell International's Cash to Debt Ratio for the quarter that ended in Feb. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.98	/	(2.395	+	9.161)
	=	0.08

Cryo-Cell International (AMEX:CCEL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Cryo-Cell International Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Cryo-Cell International's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Cryo-Cell International (Cryo-Cell International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cryo-Cell International Inc (AMEX:CCEL) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

ZCY:Germany

Address

700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677

Website

https://www.cryo-cell.com

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of Prepacyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. All the business activity of the group functions through the United States and it derives revenue from processing and testing fees and storage fees charged each year for storage and through sales of the Prepacyte CB units.

Executives

David Portnoy	director, officer: Co-Chief Executive Officer	C/O FOCUS FINANCIAL GROUP, 61 HARBOUR WAY, BAL HARBOUR FL 33154
George Gaines	director	700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Jonathan H. Wheeler	director	700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Brian L. Sheehy	director	415 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Mark L. Portnoy	director, officer: Co-Chief Executive Officer	700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Harold D. Berger	director	700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Arthur Ellis	director	700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Mary J Nyberg	10 percent owner	455 E MAYO BLVD, UNIT 5202, PHOENIX AZ 85050
Cdmj Nyberg Family Trust	10 percent owner	455 E MAYO BLVD, UNIT 5202, PHOENIX AZ 85050
Jill M Taymans	officer: VP, Finance, CFO
Oleg Mikulinsky	officer: Chief Information Officer	700 BROOKER CREEK BLVD., SUITE 1800, OLDSMAR FL 34677
Anthony Atala	director	700 BROOKER CREEK BOULEVARD, OLDSMAR FL 34677
Scott G Christian	director
Sung Won Sohn	director	700 BROOKER CREEK BLVD., SUITE 1800, OLDSMAR FL 34677
Michael W. Cho	director	C/O IOWA STATE UNIVERSITY, 1600 S. 16TH STREET, AMES IA 50011-1250